Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369343 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5612545 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL3602584 | 0.98 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5013082 | 0.98 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23082607 | 0.88 | DPP4 (0.79) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL13525327 | 0.86 | DPP4 (0.75) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL18281110 | 0.85 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL5068240 | 0.85 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8290707 | 0.83 | DPP4 (0.71) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL15636202 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292300-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT FO DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-19 | — | — | EP | claimed |
| WO-2001097808-A1 | COMBINATIONS OF DEPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-27 | — | — | WO | claimed |
| US-8759295-B2 | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2079469-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1948149-A2 | FORMULATION COMPRISING METFORMIN AND VILDAGLIPTIN | Novartis Pharma AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008057337-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | NOVARTIS AG (CH) | 2008-05-15 | — | — | WO | disclosed |
| EP-1841413-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| EP-1786401-A1 | FAST RELEASE COMPOSITION INCLUDING MELT GRANULES OF A MOISTURE SENSITIVE DRUG AND PROCESS FOR MANUFACTURING THEREOF | Novartis AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007041053-A2 | FORMULATION COMPRISING METFORMIN AND VILDAGLI PTIN | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006078593-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006021455-A1 | FAST RELEASE COMPOSITION INCLUDING MELT GRANULES OF A MOISTURE SENSITIVE DRUG AND PROCESS FOR MANUFACTURING THEREOF | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005117861-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-1292300-A1 | COMBINATIONS OD DIPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT FO DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001097808-A1 | COMBINATIONS OF DEPEPTIDYL PEPTIDASE IV INHIBITORS AND OTHER ANTIDIABETIC AGENTS FOR THE TREATMENT OF DIABETE MELLITUS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.